Esperite N.V. announced that AGAATA innovates a fully integrated and certified CE-IVD Diagnostic System with machine learning capabilities. AGAATA for clinical laboratories is designed to run in-house sensitive genetic tests delivering the fastest and accurate results. Machine learning is a subset of artificial intelligence in the field of computer programming that uses statistical techniques and acquisition of new information. AGAATA has the ability to learn and progressively improve performance on specificity and sensitivity. AGAATA is a unique system for multiple diagnoses. It runs and monitors various genetic tests in connection with the different standard next-generation sequencing equipment of clinical laboratories. Elaborated interfaces assist the qualified decision maker with extensive information about each sample and machine learning tools accelerate the diagnosis. A large portfolio of innovative tests based on DNA analysis for karyotyping, cancer predisposition, reproductive health and inherited diseases is accessible, benefiting of a robust, accurate, automated workflow comprising instruments and analysis software. The scope includes all types of DNA, for karyotyping, Breast and Ovarian cancers, Colorectal cancers, Uterine, Gastric, Pancreatic, Melanoma, Prostate, Kidney and Bladder cancers as well as Cystic Fibrosis & B-Thalassemia and any other Gene panel. The exclusive multi-layer operating AGAATA diagnostic system offers traceability, and standard laboratory equipment. AGAATA provides powerful and automatized bioinformatics analysis to deliver comprehensive clinical reports, fully automated, with a short turnaround time. Therefore, this cutting edge turnkey solution accelerates any genetic laboratory, the only CE-IVD system with such a range of CE-IVD genetic tests.